NCT04611386

The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors

Bursa Postgraduate Hospital

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 65 (actual)
• Sponsor: Bursa Postgraduate Hospital · Academic / Other
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.

Detailed description

The study included 65 people who underwent contrast computerized tomography (CT). The study patients were divided into 4 groups. Patients in group 1 were using rivaroxaban (20 patients), patients in group 2 were using apixaban (20 patients), patients in group 3 were using edoxaban (20 patients), and group 4 was the control group (5 volunteers). Iohexol (60 ml) was used as a contrast agent. Two tubes were used to collect 2 ml of blood from the patients at 4 hours after the drug dose (rivaroxaban, apixaban, or edoxaban) and 1 hour after the contrast CT (CT was performed 3 hours after the drug was taken). In the control group, at any time and 1 hour after contrast CT, 2 tubes of 2 ml of blood were collected. The anticoagulant properties of rivaroxaban, apixaban, and edoxaban were evaluated using anti-factor Xa levels.

Conditions

• Contrast Agents and Oral Factor Xa Inhibitor

Interventions

Type	Name	Description
DRUG	computerized tomography	Anti Factor Xa level

Timeline

• Start date: 2019-01-01
• Primary completion: 2019-07-01
• Completion: 2019-08-01
• First posted: 2020-11-02
• Last updated: 2020-11-02

Locations

1 site across 1 country: Turkey (Türkiye)

Regulatory

• FDA-regulated drug study